AZN.L - AstraZeneca PLC
| Previous close | 7,377.00 |
| Open | 7,342.00 |
| Bid | 7,503.00 x 0 |
| Ask | 7,511.00 x 0 |
| Day's range | 7,340.00 - 7,565.00 |
| 52-week range | 109.51 - 72,750.00 |
| Volume | 1,920,686 |
| Avg. volume | 1,830,504 |
| Market cap | 98.69B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 73.30 |
| EPS (TTM) | 102.60 |
| Earnings date | 29 Apr 2020 |
| Forward dividend & yield | 2.18 (2.99%) |
| Ex-dividend date | 27 Feb 2020 |
| 1y target est | 78.83 |
- Fool.co.uk
Why I’d avoid AstraZeneca shares and buy this FTSE 100 stock
Roland Head isn't comfortable with AstraZeneca's latest results. He reckons there's better value elsewhere in the FTSE 100 (INDEXFTSE: UKX).The post Why I'd avoid AstraZeneca shares and buy this FTSE 100 stock appeared first on The Motley Fool UK.
- Reuters - UK Focus
LIVE MARKETS-Closing snapshot: V-day of records
* STOXX 600 hits fresh record highs * German GDP disappoints * EDF tops STOXX 600 after beating forecast * RBS shares drop after results Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters. You can share your thoughts with Thyagaraju Adinarayan (thyagaraju.adinarayan@tr.com), Joice Alves (joice.alves@tr.com), Julien Ponthus (julien.ponthus@tr.com) in London and Danilo Masoni (danilo.masoni@tr.com) in Milan. CLOSING SNAPSHOT: V-DAY OF RECORDS (1640 GMT) Here it comes a good reason to celebrate this Valentine's Day: the STOXX 600 hit record highs today, again!
- Zacks
AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates
AstraZeneca (AZN) misses estimates for earnings and sales. However, new drugs, mainly cancer medicines, continue to drive product sales higher.
- Reuters - UK Focus
LIVE MARKETS-A rate cut every five days
* STOXX 600 hits fresh record highs * German GDP disappoints * EDF tops STOXX 600 after beating forecast * RBS shares drop after results * Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters. You can share your thoughts with Thyagaraju Adinarayan (thyagaraju.adinarayan@tr.com), Joice Alves (joice.alves@tr.com), Julien Ponthus (julien.ponthus@tr.com) in London and Danilo Masoni (danilo.masoni@tr.com) in Milan. A RATE CUT EVERY FIVE DAYS (1405 GMT) When Mexico decided to cut rates yesterday little did they know they'd be the 800th to do so since the global financial crisis (H/T to BofA on the rate cut count).
- Reuters - UK Focus
GLOBAL MARKETS-European stocks climb to record on hopes of limited coronavirus economic hit
Stock markets across the world ticked higher on Friday, as investors bet that the damage to the global economy from China's coronavirus outbreak would not be long-lasting. Europe's broad Euro STOXX 600 hit a record high, gaining 0.1% to mirror gains in Asia after a choppy start to the day. Indexes in London and Frankfurt gained 0.1% and 0.2% respectively, with the former moving higher after AstraZeneca shares turned positive.
- Reuters - UK Focus
LIVE MARKETS-Much love for France on Valentine's Day
* STOXX 600 hits fresh record highs * German GDP disappoints * EDF tops STOXX 600 after beating forecast * RBS shares drop after results * Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters. You can share your thoughts with Thyagaraju Adinarayan (thyagaraju.adinarayan@tr.com), Joice Alves (joice.alves@tr.com), Julien Ponthus (julien.ponthus@tr.com) in London and Danilo Masoni (danilo.masoni@tr.com) in Milan. MUCH LOVE FOR FRANCE ON VALENTINE'S DAY (1157 GMT) If you look at the top movers today, there is an eye-catching French utility topping the pan-European index: EDF - the stock gained more than 9% after the company beat forecasts.
- Reuters
AstraZeneca's CEO reaffirms 2021 targets
AstraZeneca is fully on track to reach its earnings goal for next year, its chief executive told Reuters on Friday after the British drugmaker's quarterly earnings missed market expectations. AstraZeneca is moving into a third year of sales growth after changes driven by Soriot and now has nine drugs with annual sales of more than $1 billion but analysts and investors have been looking for clues whether the company's earnings growth would keep up. The company's 2019 operating margin, or earnings before interest and tax over total revenue, was 26%.
- Fool.co.uk
Why I’d buy the AstraZeneca (AZN) share price for a second income stream
The AstraZeneca (LON: AZN) share price is soaring, and here's why I think there's more to come.The post Why I'd buy the AstraZeneca (AZN) share price for a second income stream appeared first on The Motley Fool UK.
- Reuters - UK Focus
GLOBAL MARKETS-European shares hit record even as coronavirus shows no signs of peaking
Stock markets across the world ticked higher on Friday, even as investors debated whether China's coronavirus outbreak would cause long-lasting damage to the global economy. Europe's broad Euro STOXX 600 hit a record high, gaining 0.2% to mirror gains in Asia after a choppy start to the day. Indexes in London and Frankfurt gained 0.2% and 0.3% respectively, with the former moving higher after AstraZeneca shares turned positive.
- Yahoo Finance UK
What to Watch: AstraZeneca warns on coronavirus, RBS rebrand and markets' stimulus hopes
A daily overview of the top business, market and economic stories you should be watching today in the UK and abroad.
- Reuters
AstraZeneca braces for coronavirus hit, but no impact so far
The company, moving into a third year of growth, predicted revenues would rise by a high single-digit to a low double-digit percentage at constant exchange rates this year, compared with 13% in 2019. Analysts are currently forecasting growth of 10%, according to Refinitiv data, although Jefferies analysts said anything below a double-digit estimate could be a disappointment.
- Reuters - UK Focus
MORNING BID EUROPE-Virus victim count rises -- and so do global stocks
China's announcement of more than 5,000 new coronavirus cases and 121 new deaths indicate the epidemic hasn't peaked yet. A pan-European index is in fact opening at record highs, buoyed by … answers on a postcard. The thinking appears to be the virus impact will not last, it’s not spreading outside China as fast as feared and above all, central banks can step in -- slower growth will bring more stimulus, or at least lower interest rates for longer.
- Reuters
FTSE 100 ends week lower after week AstraZeneca, RBS results
The FTSE 100 index ended the Valentine's Day trading session 0.6% lower, down 0.8% for the week, while the midcap bourse rose 0.5% as it drew strength from the pound. Global markets are expecting stimulus from central banks as new coronavirus showed no signs of peaking. U.S. Federal Reserve Chair Jerome Powell had last week warned that the economic impact from the outbreak could spill over globally.
- Reuters - UK Focus
AstraZeneca says 2020 sales growth to take coronavirus hit
AstraZeneca expects 2020 revenue growth in the high single-digit to low double-digit percentages, including a hit it now expects from the coronavirus outbreak in China, its second biggest market, the British drugmaker said on Friday. The company said the guidance assumed an unfavourable impact from China lasting up to a few months as a result of the outbreak, which has killed over 1,300 people and is still spreading.
- Reuters - UK Focus
FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials
The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of dollars to harness the potential of the Asian economic powerhouse. The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc.
- Fool.co.uk
Bitcoin will lose you money! I think these 2 FTSE 100 shares should make you richer
Andy Ross looks at two FTSE 100 shares that combine income and growth potential and could deliver big returns for investors. The post Bitcoin will lose you money! I think these 2 FTSE 100 shares should make you richer appeared first on The Motley Fool UK.
- Zacks
What's in Store for AstraZeneca (AZN) This Earnings Season?
AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.
- Fool.co.uk
Forget buy-to-let and a Cash ISA! I’d invest in these 2 FTSE 100 stocks today
These two FTSE 100 (INDEXFTSE:UKX) shares could offer long-term growth potential in my opinion.The post Forget buy-to-let and a Cash ISA! I’d invest in these 2 FTSE 100 stocks today appeared first on The Motley Fool UK.
- Fool.co.uk
I’d buy these 2 FTSE 100 dividend stocks to retire on today
These defensive FTSE 100 income stocks could help you retire on a rising, passive income. The post I'd buy these 2 FTSE 100 dividend stocks to retire on today appeared first on The Motley Fool UK.
- Business Wire
Educational Lung Cancer Event Coming to The Villages to Raise Awareness of the State’s High Rate of Lung Cancer
In an effort to show how advances in science are being harnessed in the fight against lung cancer, The LungXperience, an educational exhibit sponsored by AstraZeneca, will be making a stop at The Villages Balloon Festival. The free exhibit, designed to help educate the public about lung cancer, will be at The Villages Polo Club on February 7 from 2 PM to 9 PM and February 8 from 2 PM to 9 PM.
- Fool.co.uk
No savings at 50? I’d buy these 2 FTSE 100 dividend shares and retire on a passive income
I reckon these two FTSE 100 shares have significant potential to boost your wealth in retirement.The post No savings at 50? I’d buy these 2 FTSE 100 dividend shares and retire on a passive income appeared first on The Motley Fool UK.
- Reuters - UK Focus
INSIGHT-On eve of Brexit, Britain faces critical test to defend drug trial crown
Britain's brightest and best drug researchers are packing their bags as clinical trials start to dwindle, leaving a nation renowned as a global leader in pharmaceutical development to face a future in the slow lane. This is a worst-case scenario outlined by some scientists and industry experts in the wake of Brexit, which they say could deprive the country of its role as Europe's leader in early-stage drug research, designing and hosting pan-EU trials. Pamela Kearns, professor of paediatric oncology at the University of Birmingham, worries that over time Britain will in particular lose out in the field of medicines that treat rare diseases and childhood cancers, where trials often need to collaborate and recruit across Europe to find enough patients.
- Stockopedia
How safe is the Astrazeneca dividend payment (LON:AZN)?
Astrazeneca (LON:AZN) is a large cap Pharmaceuticals operator focused on the discovery and development of products, which are then manufactured, marketed and s8230;
